Pulmonary vasculitis and rheumatic diseases

Seminars in Respiratory and Critical Care Medicine

Volumn 19, Issue 1, 1998, Pages 57-67

  Van Den Bogaerde, J ^a   Beynon, H L C ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Connective tissue diseases; Primary vasculitides; Pulmonary vasculitis

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; PREDNISOLONE;

ANTIPHOSPHOLIPID SYNDROME; AORTA ARCH SYNDROME; ARTICLE; BEHCET DISEASE; CONNECTIVE TISSUE DISEASE; DERMATOMYOSITIS; GIANT CELL ARTERITIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENETICS; INTRAVENOUS DRUG ADMINISTRATION; LUNG BLOOD VESSEL; ORAL DRUG ADMINISTRATION; PATHOGENESIS; POLYMYOSITIS; PRIORITY JOURNAL; RELAPSING POLYCHONDRITIS; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SARCOIDOSIS; SJOEGREN SYNDROME; SYSTEMIC SCLEROSIS; VASCULITIS;

EID: 0031898411     PISSN: 10693424     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1009382     Document Type: Article

References (118)

1. Wolheim FA. Rheumatoid arthritis, the clinical picture. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford Textbook of Rheumatology New York: Oxford Medical Publications, 1993: 639-66
2. Tiwari JL, Terasaki PI. HLA-DR and disease associations. Prog Clin Biol Res 1981;58:151-63
3. Mu H, Charmley P, King MC, Criswell LA. Synergy between T cell receptor beta gene polymorphism and HLA-DR4 in susceptibility to rheumatoid arthritis. Arthritis Rheum 1996;39:931-7
4. Vollertsen RS, Conn DL, Vasculitis associated with rheumatoid arthritis. Rheum Dis Clin North Am 1990;16:445-62
5. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24
6. Hurd ER. Extraarticular manifestations of rheumatoid arthritis. Semin Arthritis Rheum 1979;8:151-76
7. Jurik AG, Davidsen D, Graudal H. Prevalence of pulmonary involvement in rheumatoid arthritis and its relationship to some characteristics of the patients A radiological and clinical study. Scand J Rheumatol 1982;11:217-24
8. Travis WD, Colby TV, Lombard C, Carpenter HA. A clinicopathologic study of 34 cases of diffuse pulmonary hemorrhage with lung biopsy confirmation. Am J Surg Pathol 1990;14:1112-25
9. Golden MR, Katz RS, Balk RA, Golden HE. The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis. J Rheumatol 1995;22:1043-7
10. Kerstens PJ, Boerbooms AM, Jeurissen ME, Fast JH, Assmann KJ, van de Putte LB. Accelerated nodulosis during low dose methotrexate therapy for rheumatoid arthritis. An analysis of ten cases [see comments]. J Rheumatol 1992;19:867-71
11. Hargreaves MR, Mowat AG, Benson MK. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: Report of five cases and review of published reports Thorax 1992;47:628-33
12. Boers M, Croonen AM, Dijkmans BA, et al. Renal findings in rheumatoid arthritis: Clinical aspects of 132 necropsies. Ann Rheum Dis 1987;46:658-63
13. Scott DG, Bacon PA, Tribe CR. Systemic rheumatoid vasculitis: A clinical and laboratory study of 50 cases. Medicine (Baltimore). 1981;60:288-97
14. Vollertsen RS, Conn DL, Ballard DJ, Ilstrup DM, Kazmar RE, Silverfield JC. Rheumatoid vasculitis: Survival and associated risk factors. Medicine (Baltimore). 1986;65: 365-75
15. Geirsson AJ, Sturfelt G, Truedsson L. Clinical and serological features of severe vasculitis in rheumatoid arthritis: prognostic implications. Ann Rheum Dis 1987;46:727-33
16. Young ID, Ford SE, Ford PM. The association of pulmonary hypertension with rheumatoid arthritis. J Rheumatol 1989;16:1266-9
17. Lee JH, Suh GY, Lee KY, et al. Small airway disease in rheumatoid arthritis. Korean J Intern Med 1992;7:87-93
18. Ippolito JA, Palmer L, Spector S, Kane PB, Gorevic PD. Bronchiolitis obliterans organizing pneumonia and rheumatoid arthritis. Semin Arthritis Rheum 1993;23: 70-8
19. Hacking JC, Flower CD. Causes and investigation of increasing dyspnoea in rheumatoid arthritis. Ann Rheum Dis 1995;54:17-9
20. Albertsen AM. Pulmonary rheumatoid nodules A rare disease onset in rheumatoid arthritis [in Danish]. Ugeskr Laeger 1993;155:3211-2
21. Grubben MJ, Kerstens PJ, Wiersma JM, Boerbooms AM, Festen J. Pleuro-pulmonary involvement in patients with connective tissue disease. The role of open lung biopsy. Neth J Med 1993;43:269-76
22. Yamakido M, Ishioka S, Takeda M. Cardiac and pulmonary manifestations in rheumatoid arthritis [in Japanese]. Nippon Rinsho 1992;50:570-5
23. Luqmani R, Watts CS, Scott DG. Treatment of vasculitis in rheumatoid arthritis. Ann Intern Med 1994;145:566-76
24. Bacon PA, Carruthers DM. Vasculitis associated with connective tissue disorders. Rheum Dis Clin North Am 1995;21:1077-96
25. Beynon HL, Athanassiou P, Davies KA Role of the endothelium in systemic lupus erythematosus and Sjögren's syndrome. In: Savage COS, Pearson JD, eds. Immunological Aspects of Vascular Endothelium. Cambridge: Cambridge University Press; 1995:124-52
26. Rosenbaum J, Pottinger BE, Whoo P, et al. Measurement and characterisation of circulating anti-endothelial cell IgG in connective tissue diseases. Clin Exp Immunol 1988;72:450-6
27. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7
28. Walport MJ Systemic lupus erythematosus. In: Lachman PJ, Peters DK, Rosen FS, Walport MJ, eds. Clinical Aspects of Immunology. Boston: Blackwell Scientific Publishers; 1993:1161-1204
29. Walport MJ, Black CM, Batchelor JR. The immunogenetics of SLE. Clin Rheum Dis 1982;8:3-21
30. Belmont HM, Buyon J, Giorno R, Abramson S. Up-regulation of endothelial cell adhesion molecules characterizes disease activity in systemic lupus erythematosus. The Shwartzman phenomenon revisited. Arthritis Rheum 1994;37:376-83
31. Yoshio T, Masuyama J, Sumiya M, Minota S, Kano S. Antiendothelial cell antibodies and their relation to pulmonary hypertension in systemic lupus erythematosus. J Rheumatol 1994;21:2058-63
32. Lie JT. Diagnostic histopathology of major systemic and pulmonary vasculitic syndromes. Rheum Dis Clin North Am 1990;16:269-92
33. Isenberg DA, Horsfall AE Systemic lupus erythematosus-adult onset. In Maddison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford Textbook of Rheumatology. New York: Oxford University Press; 1993:733-55
34. Nakamura K, Akizuki M, Ichikawa Y, Mukat M, Satoh M. Occurrence of bronchiolitis obliterans organizing pneumonia (BOOP) in a flare-up stage of systemic lupus erythematosus (SLE) [In Japanese]. Ryumachi 1993;33:156-61
35. Laroche CM, Mulvey DA, Hawkins PN, et al. Diaphragm strength in the shrinking lung syndrome of systemic lupus erythematosus. OJM 1989;71:429-39
36. Gabazza E, Taguchi O, Yamakami T, et al Usefulness of DLco for the early diagnosis of pulmonary involvement in collagen diseases [In Japanese]. Nippon Kyobu Shikkan Gakkai Zasshi 1993;31:480-5
37. Haupt HM, Moore GW, Hutchins GM. The lung in systemic lupus erythematosus. Analysis of the pathologic changes in 120 patients. Am J Med 1981;71:791-8
38. Roncoroni AJ, Alvarez C, Molinas F. Plexogenic arteriopathy associated with pulmonary vasculitis in systemic lupus erythematosus. Respiration 1992;59:52-6
39. Nair SS, Askari AD, Popelka CG, Klemerman JF. Pulmonary hypertension and systemic lupus erythematosus. Arch Intern Med 1980;140:109-11
40. Mintz G, Galindo LF, Fernandez Diez J, et al. Acute massive pulmonary hemorrhage in systemic lupus erythematosus. J Rheumatol 1978;5:39-50
41. Asherson RA, Hackett D, Gharavi AE, et al. Pulmonary hypertension in systemic lupus erythematosus: a report of three cases. J Rheumatol 1986;13:416-20
42. Hanly JG, Hong C, Zayed E, Jones JV, Jones E. Immunomodulating effects of synchronised plasmapheresis and intravenous bolus cyclophosphamide in systemic lupus erythematosus. Lupus 1995;4:457-63
43. Asherson RA, Balchelor JR, Krausz T, Hughes GR. Hypocomplementaemic urticanal vasculitis, angio-oedema and "lupus-like" disease: Association with C4B null allele. Clin Exp Rheumatol 1987;5:161-4
44. Wisnieski JJ, Baer AN, Christensen J, et al. Hypocomplementemic urticarial vasculitis syndrome. Clinical and serologic findings in 18 patients. Medicine (Baltimore). 1995;74:24-41
45. D'Cruz DP, Wisnieski JJ, Asherson RA, Khamashta MA, Hughes GR. Autoantibodies in systemic lupus erythematosus and urticarial vasculitis. J Rheumatol 1995;22: 1669-73
46. Lin RY, Caren CB, Menikoff H. Hypocomplementaemic urticarial vasculitis, interstitial lung disease and hepatitis C. Br J Dermatol 1995;132:821-3
47. Bowles CA. Vasculopathy associated with the antiphospholipid antibody syndrome. Rheum Dis Clin North Am 1990;16:471-90
48. Gastineau DA, Kazmier FJ, Nichols WL, Bowie EJ. Lupus anticoagulant: An analysis of the clinical and laboratory features of 219 cases. Am J Hematol 1985;19:265-75
49. Chartash EK, Lans DM, Paget SA, Qamar T, Lockshin MD. Aortic insufficiency and mitral regurgitation in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Am J Med 1989;86:407-12
50. Beynon HL, Walport MJ. Antiphospholipid antibodies and cardiovascular disease. Br Heart J 1992;67:281-4
51. Tsutsumi A, Matsuura E, Ichikawa K, et al. Antibodies to beta 2-glycoprotein I and clinical manifestations in patients with systemic lupus erythematosus [see comments]. Arthritis Rheum 1996;39:1466-74
52. Katano K., Aoki A, Sasa H, et al. Beta 2-glycoprotein I-dependent anticardiolipin antibodies as a predictor of adverse pregnancy outcomes in healthy pregnant women. Hum Reprod 1996;11:509-12
53. Harris NE, Pierangeli S. What is the "true" antigen for antiphospholipid antibodies? [see comments]. Lancet 1990; 336:1505
54. Khamashta MA, Cuadrado MJ. Mujic F, et al. The management of thrombosis in the antiphospholipid-antibody syndrome [see comments]. N Engl J Med 1995;332:993-7
55. Ehrenfeld M, Shoenfeld Y. Haematology and oncology in rheumatology. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford Textbook of Rheumatology. New York: Oxford Medical Publications; 1993:154-62
56. Fox RI, Pearson G, Vaughan JH. Detection of Epstein-Barr virus-associated antigens and DNA in salivary gland biopsies from patients with Sjögren's syndrome. J Immunol 1986;137:3162-8
57. Miyasaka N, Yamaoka K, Sato K, et al. An analysis of polyclonal B cell activation in Sjögren's syndrome. Characterization of B cell lines spontaneously established from the peripheral blood. Scand J Rheumatol Suppl 1986;61: 123-6
58. Kraus A, Caballero Uribe C, Jakez J, Villa AR, Alarcon Segovia D Raynaud's phenomenon in primary Sjögren's syndrome. Association with other extraglandular manifestations. J Rheumatol 1992;19:1572-4
59. Ferreiro JE, Robalmo BD, Saldana MJ. Primary Sjögren's syndrome with diffuse cerebral vasculitis and lymphocytic interstitial pneumonitis. Am J Med 1987;82:1227-32
60. Rosen Y, Vuletin JC, Pertschuk LP, Silverstein E. Sarcoidosis: From the pathologist's vantage point. Pathol Annu 1979;14(Pt I):405-39
61. Travis WD, Fleming MV. Vasculitis of the lung. Pathology (Phila). 1996;4:23-41
62. Smith LJ, Lawrence JB, Katzenstein AA. Vascular sarcoidosis: A rare cause of pulmonary hypertension. Am J Med Sci 1983;285:38-44
63. Niimi H, Hartman TE, Muller NL. Necrotizing sarcoid granulomatosis: Computed tomography and pathologic findings. J Comput Assist Tomogr. 1995;19:920-3
64. Churg A, Carrington CB, Gupta R. Necrotizing sarcoid granulomatosis. Chest 1979;76:406-13
65. Marguerie C, Bunn CC, Beynon HL, et al. Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes. QJM 1990;77:1019-38
66. Tamaki T, Mori S, Takehara K Epidemiological study of patients with systemic sclerosis in Tokyo Arch Dermatol Res 1991;283:366-71
67. Isenberg DA, Black C: ABC of rheumatology. Raynaud's phenomenon, scleroderma, and overlap syndromes. BMJ 1995;310:795-8
68. Denton CP, Bickerstaff MC, Shiwen X, et al. Serial circulating adhesion molecule levels reflect disease severity in systemic sclerosis. Br J Rheumatol 1995;34:1048-54
69. Kahaleh MB. The role of vascular endothelium in Fibroblast activation and tissue fibrosis, particularly in scleroderma (systemic sclerosis) and pachydermoperiostosis (primary hypertrophic osteoarthropathy). Clin Exp Rheumatol 1992;10(suppl 7):51-6
70. Koh ET, Lee P, Gladman DD. Abu Shakra M. Pulmonary hypertension in systemic sclerosis: An analysis of 17 patients. Br J Rheumatol 1996;35:989-93
71. Herrick AL, Oogarah PK, Freemont AJ, et al. Vasculitis in patients with systemic sclerosis and severe digital ischaemia requiring amputation. Ann Rheum Dis 1994;53: 323-6
72. Steen VD, Lanz JK, Jr., Conte C, Owens GR, Medsger TA, Jr. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum 1994;37: 1290-6
73. Yazici H Behcet's syndrome. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford Textbook of Rheumatology. New York: Oxford University Press; 1993:884-9
74. International Study Group for Behcet's disease. Criteria for diagnosis of Behcet's disease. Lancet 1990;335:1078-80
75. O'Duffy JD. Vasculitis in Behcet's disease. Rheum Dis Clin North Am 1990;15:423-31
76. Kansu E, Ozer FL, Akalin E, et al Behcet's syndrome with obstruction of the venae cavae. A report of seven cases. OJM 1972;41:151-68
77. O'Duffy JD, Carney JA, Doedhar S. Behcet's disease Report of 10 cases, 3 with new manifestations. Ann Intern Med 1971;75:561-70
78. Slavin RE, de Groot WJ. Pathology of the lung in Behcet's disease. Case report and review of the literature. Am J Surg Pathol 1981;5:779-88
79. Salamon F, Weinberger A, Nili M, et al. Massive hemoptysis complicating Behcet's syndrome: The importance of early pulmonary angiography and operation. Ann Thorac Surg 1988;45:566-7
80. Irani BS, Martin Hirsch DP, Clark D, et al. Relapsing polychondritis - a study of four cases. J Laryngol Otol 1992; 106:911-4
81. Harisdangkul V, Johnson WW. Association between relapsing polychondritis and systemic lupus erythematosus South Med J 1994;87:753-7
82. Michet CJ. Vasculitis and relapsing polychondritis. Rheum Dis Clin North Am 1990;16:441-4
83. Lang B, Rothenfusser A, Lanchbury JS, et al. Susceptibility to relapsing polychondritis is associated with HLA-DR4. Arthritis Rheum 1993;36:660-4
84. Eng J, Sabanathan S. Airway complications in relapsing polychondritis. Ann Thorac Surg 1991;51:686-92
85. Bowness P, Hawley IC, Morris T, Dearden A, Walport MJ. Complete heart block and severe aortic incompetence in relapsing polychondritis. Clinicopathologic findings Arthritis Rheum 1991;34:97-100
86. Dunne JA, Sabanathan S. Use of metallic stems in relapsing polychondritis. Chest 1994;105:864-7
87. Firestein GS, Gruber HE, Weisman MH, et al. Mouth and genital ulcers with inflamed cartilage: MAGIC syndrome Five patients with features of relapsing polychondritis and Behcet's disease. Am J Med 1985;79:65-72
88. Klein RG, Hunder GG, Stanson AW, Sheps SG. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med 1975;83:806-12
89. Machado EB, Michet CJ, Ballard DJ, et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950-1985. Arthritis Rheum 1988;31:745-9
90. Glover MU, Muniz J, Bessone L, et al. Pulmonary artery obstruction due to giant cell arteritis. Chest 1987;91:924-5
91. Kramer MR, Melzer E, Nesher G, Sonnenblick M. Pulmonary manifestations of temporal arteritis. Eur J Respir Dis 1987;71:430-3
92. Vered Z, Pras M, Horowitz A, Rath S, Neufeld HN. Severe aortic regurgitation. A rare presentation of giant cell arteritis. Clin Cardiol 1986;9:509-11
93. Nishino H, DeRemee RA, Rubino FA, Parisi JE. Wegener's granulomatosis associated with vasculitis of the temporal artery: Report of five cases ]see comments]. Mayo Clin Proc 1993;68:115-21
94. Amato MB, Barbas CS, Delmonte VC, Carvalho CR. Concurrent Churg-Strauss syndrome and temporal arteritis in a young patient with pulmonary nodules. Am Rev Respir Dis 1989;139:1539-42
95. Hunder GG. Giant cell (temporal) arteritis. Rheum Dis Clin North Am 1990;16:399-409
96. Andersson R, Malmvall BE, Bengtsson BA. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 1986;220:465-9
97. Fauci AS, Haynes BF, Katz P, Wolff SM. Wegener's granulomatosis: Prospective clinical and therapeutic experience with 85 patients for 21 years. Ann Intern Med 1983;98: 76-85
98. Schultz DR, Tozman EC. Antineutrophil cytoplasmic antibodies: Major autoantigens, pathophysiology, and disease associations. Semin Arthritis Rheum 1995;25:143-59
99. Niles JL. Value of tests for antineutrophil cytoplasmic autoantibodies in the diagnosis and treatment of vasculitis. Curr Opin Rheumatol 1993;5:18-24
100. Penas PF, Porras JI, Fraga J, et al. Microscopic polyangiitis. A systemic vasculitis with a positive P-ANCA. Br J Dermatol 1996;134:542-7
101. Niles JL. Antineutrophil cytoplasmic antibodies in the classification of vasculitis. Annu Rev Med 1996;47:303-13
102. Hauschild S, Schmitt WH, Csernok E, et al. ANCA in systemic vasculitides, collagen vascular diseases, rheumatic disorders and inflammatory bowel diseases. Adv Exp Med Biol 1993;336:245-51
103. Schubert F, Muhle C, Schnabel A, et al. High-resolution CT (HRCT) of the lung in Wegener's granulomatosis [In German.] Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr 1994;161:19-24
104. Tojima H, Kinoshita T, Kasahara Y, et al. A case of Wegener's granulomatosis with episcleritis, mediastinal lesions, and pleural effusion and without serum anti-neutrophil cytoplasmic antibodies [In Japanese]. Nippon Kyobu Shikkan Gakkai Zasshi 1994;32:62-7
105. Weir IH, Muller NL, Chiles C, et al. Wegener's granulomatosis: Findings from computed tomography of the chest in 10 patients. Can Assoc Radiol J 1992;43:31-4
106. Guillevin L, Lhote F. Polyarteritis nodosa and microscopic polyangiitis. Clin Exp Immunol 1995;101 (suppl 1):22-3
107. Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: A clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). 1984;63:65-81
108. Chumbley LC, Harrison EG, Jr., DeRemee RA. Allergic granulomatosis and angiitis (Churg-Strauss syndrome). Report and analysis of 30 cases. Mayo Clin Proc 1977;52: 477-84
109. Nakagawa A, Yamaguchi T, Amano H, Takao T. A case of Churg-Strauss syndrome in which MPO-ANCA (antibodies to myeloperoxidase) appeared to reflect the disease activity [In Japanese]. Nippon Kyobu Shikkan Gakkai Zasshi 1995;33:543-7
110. Lupi E, Sanchez G, Horwitz S, Gutierrez E. Pulmonary artery involvement in Takayasu's arteritis. Chest 1975;67: 69-74
111. Ogawa Y, Hayashi K, Sakamoto I, Matsunaga N. Pulmonary arterial lesions in Takayasu arteritis: Relationship of inflammatory activity to scintigraphic findings and sequential changes. Ann Nucl Med 1996;10:219-23
112. Greene NB, Baughman RP, Kim CK. Takayasu's arteritis associated with interstitial lung disease and glomerulonephritis. Chest 1986;89:605-6
113. Hall S, Barr W, Lie JT, et al. Takayasu arteritis. A study of 32 North American patients. Medicine (Baltimore). 1985; 64:89-99
114. Pajari R, Hekali P, Harjola PT. Treatment of Takayasu's arteritis: An analysis of 29 operated patients. Thorac Cardiovasc Surg 1986;34:176-81
115. Brouet JC, Clauvel JP, Danon F, Klein M, Seligmann M. Biologic and clinical significance of cryoglobulins. A report of 86 cases. Ann J Med 1974;57:775-88
116. Invernizzi F, Galli M, Serino G, et al. Secondary and essential cryoglobulinemias. Frequency, nosological classification, and long-term follow-up. Acta Haematol 1983;70: 73-82
117. Ferri C, Greco F, Longombardo G, et al. Antibodies against hepatitis C virus in mixed cryoglobulinemia patients. Infection 1991;19:417-20
118. Geltner D, Kohn R, Gorevic PD, Franklin CM. The effect of combination therapy (steroids, immunosuppressives, and plasmapheresis) on 5 mixed cryoglobulinaemia patients with renal, neurologic, and vascular involvement. Arthritis Rheum 1981;24:1121-7